MetLife has delivered a strong 82.3% total return over the past five years, yet today the stock screens as expensive on traditional multiples while an Excess Returns intrinsic value estimate points to meaningful upside, so investors are getting mixed signals on what the current US$96.73 share price really implies. Over five years, MetLife has returned 82.3%, which puts recent valuation concerns in the context of a stock that has already created substantial shareholder value over a longer...

When the 30-year Treasury topped 5%, two dividend stocks moved in completely opposite directions on the same day, and the reason has nothing to do with their yields.

BlackRock, DLocal, Chevron, Williams Companies, and MetLife pay solid dividends and carry favorable analyst ratings, offering income investors growth exposure and price target upside.

MetLife’s second quarter results were marked by broad-based earnings growth, with market participants rewarding the company’s performance as shares rose notably after the announcement. Management attributed the positive momentum to strong underwriting across all segments, increased international sales, and disciplined expense controls. CEO Michel Khalaf pointed to the impact of MetLife’s “New Frontier strategy,” which leverages recurring revenue streams and a diverse global portfolio, emphasizin

Adjusted earnings surged 15% on strong underwriting and broad-based volume growth.

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.

MetLife (NYSE:MET) reported second-quarter 2026 adjusted earnings of approximately $1.6 billion, or $2.43 per share, up 15% from a year earlier. Adjusted earnings per share increased 20%, while adjusted return on equity reached 17%, the top end of the company’s 15% to 17% annual target range. Presi

American International beats Q2 earnings estimates as stronger underwriting and lower catastrophe losses offset weaker investment income.

Aflac's Q2 adjusted EPS misses estimates as lower investment income and FX weigh, but U.S. sales, policy persistency and capital returns offer support.

MetLife has outperformed the broader market over the past year, and analysts are cautiously optimistic about the stock’s prospects.

MetLife (NYSE: MET) announced that its board of directors has approved a new US$3b share repurchase authorization. The buyback authorization adds a fresh layer to MetLife's capital return plans and offers the board flexibility over future share repurchases. The decision signals the insurer's confidence in its balance sheet and long term capital allocation approach. MetLife is far from the only large insurer using buybacks and dividends to return capital to investors. It is therefore worth...

MET tops Q2 EPS estimates as higher investment income, favorable underwriting and business volume growth lift earnings despite higher expenses.